High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Anders Nissen Bonde

Roskilde University Hospital, Roskilde (Denmark)

8 More presentations in this session

Presentation thumbnail

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Doctor T. Chao (Taipei, TW)

Presentation thumbnail

Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Doctor P. Rasmussen (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Professor J. Hartikainen (Kuopio, FI)

Abstract Slides

Presentation thumbnail

Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Associate Professor S. Choi (Daegu, KR)

Abstract Slides

Presentation thumbnail

Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Doctor G. Vanerio (Montevideo, UY)

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Session

EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources